Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKE | Q14164 | 3/20 | 0.48 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.48 |
| ▸ | ILK | Q13418 | 2/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 11/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27029460 | 0.88 | TBK1 (0.45) | IKBKETBK1ILKTGFBR1LRRK2 | |
| SCHEMBL29859768 | 0.81 | IKBKE (0.38) | IKBKETBK1ILKTGFBR1LRRK2 | |
| Hydrochloric Acid SCHEMBL2589518 | 0.72 | IKBKE (0.35) | IKBKETBK1ILKTGFBR1 | |
| SCHEMBL2728413 | 0.71 | HTR2B (0.48) | IKBKETBK1ILKGPR35 | |
| Hydrochloric Acid SCHEMBL31122121 | 0.70 | CHEK1 (0.47) | IKBKETBK1ILKGPR35 | |
| SCHEMBL30388731 | 0.69 | MAPK1 (0.41) | IKBKETBK1LRRK2GPR35PLK1 | |
| SCHEMBL13735539 | 0.68 | LRRK2 (0.39) | IKBKETBK1LRRK2GPR35PLK1 | |
| SCHEMBL611638 | 0.68 | CDC7 (0.41) | IKBKETBK1GPR35PLK1 | |
| SCHEMBL30387828 | 0.67 | LRRK2 (0.38) | IKBKETBK1LRRK2PLK1 | |
| SCHEMBL28988096 | 0.67 | LRRK2 (0.38) | IKBKETBK1LRRK2PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326778-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4308115-A1 | HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197577-A1 | HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326778-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | IKBKE 19/4885TBK1 9/4885ILK 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.